Top

Published in:

Open Access 01-12-2017 | Review

Review article: effects of type 2 diabetes therapies on bone metabolism

Authors: A. G. D. Vianna, C. P. Sanches, F. C. Barreto

Published in: Diabetology & Metabolic Syndrome | Issue 1/2017

Abstract

Diabetes complications and osteoporotic fractures are two of the most important causes of morbidity and mortality in older patients, and they share many features, including genetic susceptibility, molecular mechanisms, and environmental factors. Type 2 diabetes mellitus (T2DM) compromises bone microarchitecture by inducing abnormal bone cell function and matrix structure with increased osteoblast apoptosis, diminished osteoblast differentiation, and enhanced osteoclast-mediated bone resorption. The linkage between these two chronic diseases creates a possibility that certain antidiabetic therapies may affect bone function. The treatment of T2DM has been improved in the past two decades with the development of new therapeutic drugs. Each class has a pathophysiologic target related to the regulation of the energy metabolism and insulin secretion. However, both glycemic homeostasis and bone homeostasis are under the control of common regulatory factors. This background allows the individual pharmacological targets of antidiabetic therapies to affect bone quality due to their indirect effects on bone cell differentiation and the bone remodeling process. With a greater number of diabetic patients and antidiabetic agents being launched, it is critical to highlight the consequences of this disease and its pharmacological agents on bone health and fracture risk. Currently, there is little scientific knowledge approaching the impact of most anti-diabetic treatments on bone quality and fracture risk. Thus, this review aims to explore the pros and cons of the available pharmacologic treatments for T2DM on bone mineral density and risk fractures in humans.

Oei L, Rivadeneira F, Zillikens MC, Oei EHG. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13(2):106–15. doi:10.1007/s11914-015-0260-5.CrossRefPubMedPubMedCentral

Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27:219–28. doi:10.1007/s00198-015-3279-7.CrossRefPubMed

Shah VN, Shah CS, Pharm M, Snell-Bergeon JK. Type 1 diabetes and risk for fracture: meta-analysis and review of the literature. Diabet Med. 2015;32(9):1134–42. doi:10.1111/dme.12734.CrossRefPubMedPubMedCentral

Liao C-C, Lin C-S, Shih C-C, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37:2246–52. doi:10.2337/dc13-2957.CrossRefPubMed

Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. Int J Endocrinol. 2014;2014:820615. doi:10.1155/2014/820615.CrossRefPubMedPubMedCentral

Schwartz AV. Diabetes, bone and glucose-lowerring agents: clinical outcomes. Diabetologia. 2017;60:1170–9. doi:10.1007/s00125-017-4283-6.CrossRefPubMed

Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13:186–91. doi:10.1007/s11914-015-0265-0.CrossRefPubMed

Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28:313–24. doi:10.1002/jbmr.1763.CrossRefPubMedPubMedCentral

Nilsson AG, Sundh D, Johansson L, et al. Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women: a population-based study. J Bone Miner Res. 2017;32(5):1062–71. doi:10.1002/jbmr.3057.CrossRefPubMed

10.

Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231–7. doi:10.1002/jbmr.1759.CrossRefPubMed

11.

Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;29(11):201. doi:10.1186/1479-5876-11-201.CrossRef

12.

Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA. IOF-IFCC bone marker standards working group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi:10.1007/s00198-010-1501-1.CrossRefPubMed

13.

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–5. doi:10.2337/dc06-1732.CrossRefPubMed

14.

Rejnmark L. Bone effects of glitazones and other anti-diabetic drugs. Curr Drug Saf. 2008;3(3):194–8. doi:10.2174/157488608785699478.CrossRefPubMed

15.

Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074–81. doi:10.2337/diabetes.51.7.2074.CrossRefPubMed

16.

Madsen A, Bozickovic O, Bjune J, et al. Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2). Sci Rep. 2015;5:16430. doi:10.1038/srep16430.CrossRefPubMedPubMedCentral

17.

McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes. 2016;7(6):122–33. doi:10.4239/wjd.v7.i6.122.CrossRefPubMedPubMedCentral

18.

Kasai T, Bandow K, Suzuki H, et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol. 2009;221(3):740–9. doi:10.1002/jcp.21917.CrossRefPubMed

19.

Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone. 2011;48(4):885–93. doi:10.1016/j.bone.2010.12.003.CrossRefPubMed

20.

Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011;112(10):2902–9. doi:10.1002/jcb.23206.CrossRefPubMed

21.

Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–51. doi:10.2337/dc07-2270.CrossRefPubMed

22.

Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(1):134–42. doi:10.1210/jc.2009-0572.CrossRefPubMed

23.

Lecka-Czernik B. Safety of antidiabetic therapies on bone. Clin Rev Bone Min Metab. 2013;11(1):49–58. doi:10.1007/s12018-012-9129-7.CrossRef

24.

Thiazolidinediones Yki-Järvinen H. N Engl J Med. 2004;351(11):1106–18. doi:10.1056/NEJMra041001.CrossRef

25.

Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194–213. doi:10.1210/er.2012-1042.CrossRefPubMed

26.

Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349–54. doi:10.1210/jc.2005-2226.CrossRefPubMedPubMedCentral

27.

Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized. Controlled Trial. J Clin Endocrinol Metab. 2007;92(4):1305–10. doi:10.1210/jc.2006-2646.CrossRefPubMed

28.

Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395–402. doi:10.1001/archinternmed.2009.214.CrossRefPubMed

29.

Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820. doi:10.1001/archinte.168.8.820.CrossRefPubMed

30.

Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):1–8. doi:10.1371/journal.pmed.1000154.CrossRef

31.

Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002;143(6):2376–84. doi:10.1210/endo.143.6.8834.CrossRefPubMed

32.

Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401–6. doi:10.1210/en.2003-0746.CrossRefPubMed

33.

Soroceanu MA. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004;183(1):203–16. doi:10.1677/joe.1.05723.CrossRefPubMed

34.

Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146(3):1226–35. doi:10.1210/en.2004-0735.CrossRefPubMed

35.

Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148(6):2669–80. doi:10.1210/en.2006-1587.CrossRefPubMedPubMedCentral

36.

Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B. PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from bone marrow mesenchymal stem cels. J Cell Biochem. 2009;106(2):232–46. doi:10.1002/jcb.21994.CrossRefPubMedPubMedCentral

37.

Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104(1):1–9. doi:10.1055/s-0029-1211414.CrossRefPubMed

38.

Lapane KL, Jesdale BM, Dubé CE, Pimentel CB, Rajpathak SN. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;109(2):411–9. doi:10.1016/j.diabres.2015.05.009.CrossRefPubMed

39.

Melton LJ III, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23(8):1334–42. doi:10.1359/jbmr.080323.CrossRefPubMedPubMedCentral

40.

Vianna AGD, de Lacerda CS, Pechmann LM, et al. Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial. Diabetol Metab Syndr. 2017;9(1):35. doi:10.1186/s13098-017-0232-2.CrossRefPubMedPubMedCentral

41.

Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept. 2003;2003(114):189–96. doi:10.1016/S0167-0115(03)00125-3.CrossRef

42.

Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32. doi:10.1172/JCI30076.CrossRefPubMedPubMedCentral

43.

Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res. 2005;20(9):1497–506. doi:10.1359/JBMR.050524.CrossRefPubMed

44.

Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007;292(2):E543–8. doi:10.1152/ajpendo.00364.2006.CrossRefPubMed

45.

Nuche-Berenguer B, Portal-Núñez S, Moreno P, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010;225(2):585–92. doi:10.1002/jcp.22243.CrossRefPubMed

46.

Xie D, Zhong Q, Ding K-H, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007;40(5):1352–60. doi:10.1016/j.bone.2007.01.007.CrossRefPubMed

47.

Reid IR, Cornish J, Baldock PA. Nutrition-related peptides and bone homeostasis. J Bone Miner Res. 2005;21(4):495–500. doi:10.1359/jbmr.051105.CrossRef

48.

Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016;81(1):78–88. doi:10.1111/bcp.12777.CrossRefPubMed

49.

Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000;141(3):1228–35. doi:10.1210/endo.141.3.7366.CrossRefPubMed

50.

Tsukiyama K, Yamada Y, Yamada C, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 2006;20(7):1644–51. doi:10.1210/me.2005-0187.CrossRefPubMed

51.

Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149(2):574–9. doi:10.1210/en.2007-1292.CrossRefPubMed

52.

Lu N, Sun H, Yu J, et al. Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE. 2015;10(7):1–15. doi:10.1371/journal.pone.0132744.

53.

Bunck MC, Eliasson B, Cornér A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):374–7. doi:10.1111/j.1463-1326.2010.01355.x.CrossRefPubMed

54.

Li R, Xu W, Luo S, et al. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2015;52(6):1083–91. doi:10.1007/s00592-015-0792-2.CrossRefPubMed

55.

Su B, Sheng H, Zhang M, Bu L, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:107–15. doi:10.1007/s12020-014-0361-4.CrossRefPubMed

56.

Driessen JH, Henry RM, van Onzenoort HA, et al. Bone fracture risk is not associated with the use of glucagon- like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. 2015;97:104–12. doi:10.1007/s00223-015-9993-5.CrossRefPubMedPubMedCentral

57.

Driessen JH, van Onzenoort HA, Starup-Linde J, et al. Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. 2015;97:506–15. doi:10.1007/s00223-015-0037-y.CrossRefPubMedPubMedCentral

58.

Fu J, Zhu J, Hao Y, Guo C, Zhou Z. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep. 2016;6(1):29104. doi:10.1038/srep29104.CrossRefPubMedPubMedCentral

59.

Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122(2):531–44. doi:10.1053/gast.2002.31068.CrossRefPubMed

60.

Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women. Bone. 2007;40(3):723–9. doi:10.1016/j.bone.2006.09.025.CrossRefPubMed

61.

Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004;34(1):140–7. doi:10.1016/j.bone.2003.09.009.CrossRefPubMed

62.

Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res. 2003;18(12):2180–9. doi:10.1359/jbmr.2003.18.12.2180.CrossRefPubMed

63.

Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD. A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009;45(5):833–42. doi:10.1016/j.bone.2009.07.008.CrossRefPubMed

64.

Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996;137(9):3674–80. doi:10.1210/endo.137.9.8756532.CrossRefPubMed

65.

Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 1996;393(2–3):248–52. doi:10.1016/0014-5793(96)00895-2.CrossRefPubMed

66.

Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-gamma activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology. 2011;152(2):457–67. doi:10.1210/en.2010-1098.CrossRefPubMed

67.

Bunck MC, Poelma M, Eekhoff EM, et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes. 2012;4(2):181–5. doi:10.1111/j.1753-0407.2011.00168.x.CrossRefPubMed

68.

Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474–6. doi:10.2337/dc11-1099.CrossRefPubMedPubMedCentral

69.

Driessen JHM, van Onzenoort HAW, Henry RMA, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014;68:124–30. doi:10.1016/j.bone.2014.07.030.CrossRefPubMed

70.

Kanai Y, Lee W, You G, Brown D, Hediger MA. The human kidney low affinity Na +/glucose cotransporter SGLT2. J Clin Invest. 1994;93(January):397–404.CrossRefPubMedPubMedCentral

71.

Nair S, Wilding JPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34–42. doi:10.1210/jc.2009-0473.CrossRefPubMed

72.

Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157–66. doi:10.1210/jc.2015-3167.CrossRefPubMed

73.

Neal B, Perkovic V, Kenneth W. Mahaffey et al. for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Jun 12. doi 10:1056/NEJMoa1611925.

74.

Harper C, Pattinson AL, Fernando HA, Zibellini J, Seimon RV, Sainsbury A. Effects of obesity treatments on bone mineral density, bone turnover and fracture risk in adults with overweight or obesity. Horm Mol Biol Clin Investig. 2016;28(3):133–49. doi:10.1515/hmbci-2016-0025.PubMed

75.

Mannucci E, Monami M. Bone fractures with sodium-glucose co-transporter-2 inhibitors: how real is the risk? Drug Saf. 2017;40(2):115–9. doi:10.1007/s40264-016-0470-5.CrossRefPubMed

76.

Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(8):1375–85. doi:10.1080/03007995.2016.1174841.CrossRefPubMed

77.

Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159–69. doi:10.1111/dom.12189.CrossRefPubMed

78.

Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990–9. doi:10.1111/j.1463-1326.2012.01630.x.CrossRefPubMed

79.

Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303. doi:10.1111/dom.12428.CrossRefPubMed

80.

Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TWA, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37(10):815–29. doi:10.1007/s40264-014-0213-4.CrossRefPubMed

81.

Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71. doi:10.1038/ki.2013.356.CrossRefPubMed

82.

Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2017;. doi:10.1002/dmrr.2903.PubMed

83.

Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199–206. doi:10.1111/dom.12742.CrossRefPubMed

84.

Thrailkill KM, Lumpkin CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735–45. doi:10.1152/ajpendo.00159.2005.CrossRefPubMedPubMedCentral

85.

Akune T, Ogata N, Hoshi K, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol. 2002;159(1):147–56. doi:10.1083/jcb.200204046.CrossRefPubMedPubMedCentral

86.

Ogata N, Chikazu D, Kubota N, et al. Insulin receptor sub- strate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest. 2000;105(7):935–43. doi:10.1172/JCI9017.CrossRefPubMedPubMedCentral

87.

Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García-Cervigón A. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000;11(5):455–9. doi:10.1007/s001980070114.CrossRefPubMed

88.

Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25(10):1749–54. doi:10.2337/diacare.25.10.1749.CrossRefPubMed

89.

Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24(7):1192–7. doi:10.2337/diacare.24.7.1192.CrossRefPubMed

90.

Borges JLC, Bilezikian JP, Jones-Leone AR, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 d. Diabetes Obes Metab. 2011;13(11):1036–46. doi:10.1111/j.1463-1326.2011.01461.x.CrossRefPubMed

91.

Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008;31:199–203. doi:10.2337/dc07-1736.CrossRefPubMed

Title: Review article: effects of type 2 diabetes therapies on bone metabolism
Authors: A. G. D. Vianna
C. P. Sanches
F. C. Barreto
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Diabetology & Metabolic Syndrome / Issue 1/2017
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-017-0274-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Review article: effects of type 2 diabetes therapies on bone metabolism

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Genetic diagnosis and treatment of a Chinese ketosis-prone MODY 3 family with depression

The burden of diabetes and hyperglycemia in Brazil-past and present: findings from the Global Burden of Disease Study 2015

Erratum to: Cardiovascular risk assessment in patients with diabetes

Association of the polymorphism in NUCB2 gene and the risk of type 2 diabetes

Prevalence of overweight and obesity in United Arab Emirates Expatriates: the UAE National Diabetes and Lifestyle Study

Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC/Q-TOF/MS analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page